



## Multidrug-Resistant *Mycobacterium tuberculosis*

Guest Editors:

**Dr. Uma Shankar Gautam**

Duke Human Vaccine Institute,  
Duke University School of  
Medicine, Durham, NC, USA

**Dr. Vinayak Singh**

Drug Discovery and Development  
Centre (H3D), University of Cape  
Town, Cape Town, South Africa

Deadline for manuscript  
submissions:

**closed (30 April 2024)**

### Message from the Guest Editors

Authors are invited to submit articles addressing antimicrobial resistance, the treatment and drug resistance of tuberculosis, multi-drug resistance, latent TB infection, transmission and reactivation, its mechanisms, drivers, spread, and new approaches to study, control, and overcome tuberculosis infection and disease.

Potential topics include, but are not limited to, the following:

- Multi-drug-resistant TB;
- Latent TB infection and TB reactivation;
- Public health, resources, and their contribution to global TB burden;
- Antimicrobial-resistant TB burden;
- Mechanisms leading to antimicrobial resistance;
- Small-molecule inhibitors of *Mycobacterium tuberculosis*;
- Omics technology for antimicrobial resistance and TB surveillance;
- Prevention of the emergence and dissemination of antimicrobial resistance;
- MDR/XDR-TB management;
- Antibiotics and inhibitors.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Nicholas Dixon

School of Chemistry and  
Molecular Bioscience, University  
of Wollongong, Wollongong, NSW  
2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1  
(*General Pharmacology, Toxicology and Pharmaceutics*)

## Contact Us

*Antibiotics* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/antibiotics](http://mdpi.com/journal/antibiotics)  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)  
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)